Primary Biliary Cholangitis (PBC) Treatment Market Competitive Growth Strategies Based on Type, Applications, End-User and Region
Primary biliary cholangitis, also called primary biliary cirrhosis, is an autoimmune disease of the liver that manifests as progressive cholestasis and leads to end-stage liver disease. Primary biliary cholangitis characterized by the destruction of the bile ducts that transport bile acid. Primary biliary cholangitis is detected at the advanced stage of the disease. Primary biliary cirrhosis mainly seen in women in the fourth or sixth decade of life. Primary biliary cholangitis usually diagnosed during a routine blood test that presents with symptoms such as fatigue, whooping cough, and right upper quadrant discomfort. During the initial examination, the disease is found to be normal, as the disease progresses, shows symptoms of cirrhosis of the liver. The hallmark of primary biliary cirrhosis is the presence of anti-mitochondrial antibodies (AMA) in the blood. Medical management of primary biliary cirrhosis is primarily aimed at slowing the progression of symptoms and alleviating symptoms.
Request a sample copy of the report: https://www.futuremarketinsights.com/reports/sample/rep-gb-3773
Primary Biliary Cholangitis Treatment Market: Drivers and Restraints
The global primary biliary cholangitis treatment market is anticipated to be driven by highly unmet medical needs owing to lack of definitive treatment, advanced diagnostic process coupled with growing awareness among healthcare professionals and patients across the world. The incidence and prevalence of primary biliary cholangitis vary geographically, ranging from 0.7 to 49 and 6.7 to 402 per million, respectively. The factors that are currently contributing to the revenue growth of the primary biliary cholangitis treatment market are increasing incidence and prevalence of the disease, increased exposure to environmental triggers of the immune system such as pesticides. Additionally, lifestyle changes such as smoking, alcoholism, and obesity are expected to drive the primary biliary cholangitis treatment market over the forecast period.
Global primary biliary cholangitis treatment market hampered by lack of definitive treatment for the disease and late diagnosis of the disease has led to treatment deprivation for the patient. The market is constrained by the lack of epidemiological data that helps to assess the access and availability of the products in various geographies, which is expected to hamper the growth of the primary biliary cholangitis treatment market revenue during the period of forecast
Primary Biliary Cholangitis Treatment Market: Overview
The global primary biliary cholangitis treatment market is witnessing significant changes owing to the recent approval of UDCA by several regulatory authorities across the globe. In May 2016, the FDA approved obeticholic acid in combination with UDCA for primary biliary cholangitis (PBC) in adult patients with an inadequate response to UDCA. The UK’s National Institute for Health and Care Excellence (NICE) and the European Commission granted marketing authorization for Ocaliva (obeticholic acid) from Intercept Pharmaceuticals, Inc. in 2017 and 2016 respectively.
Request a report brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3773
Primary Biliary Cholangitis Treatment Market: Outlook by Region
Geographically, the primary biliary cholangitis treatment market is categorized into regions, viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Western Europe will remain key markets for primary biliary cholangitis treatment products due to increasing regulatory approvals for treatment options. . Asia-Pacific is expected to present better growth opportunities due to a large untapped market, rising personal spending, and increasing government interventions to improve healthcare infrastructure in the region.
Primary Biliary Cholangitis Treatment Market: Key Players
Some of the global biliary cholangitis primary treatment market players are Intercept Pharmaceuticals, Inc., Actavis, Inc., Teva Pharmaceuticals Inc., Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Axcan Scandipharm Inc., to name only a few.
The research report presents a comprehensive assessment of the market and contains thoughtful information, facts, historical data and market data backed by statistics and validated by the industry. It also contains projections using an appropriate set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
Get Personalization In The Report, Inquire [email protected] https://www.futuremarketinsights.com/customization-available/rep-gb-3773
Primary Biliary Cholangitis Treatment Market: Segmentation
The global primary biliary cholangitis treatment market has been segmented on the basis of treatment type, end-user, and region.
Based on Treatment Type, the Global Primary Biliary Cholangitis Treatment Market is segmented as follows:
- For treatment
- Ursodeoxycholic acid
- Obeticholic acid
- For symptom control
- Opioid antagonists
On the basis of end-user, the global primary biliary cholangitis treatment market is segmented as follows:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies